Avenue Therapeutics Inc (ATXI)
OTHER OTC:ATXI
Top Page
Avenue Therapeutics
(OTC:ATXI)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.16
▼(-77.67% Downside)
Action:ReiteratedDate:02/03/26
The score is held back mainly by weak financial quality (ongoing losses and negative free cash flow despite improvement) and very bearish technicals (price well below key moving averages with negative MACD). Valuation is constrained by a negative P/E and no dividend, while recent corporate events provide some offset through a positive asset-sale transaction and governance stability.
Positive Factors
Debt-free balance sheet
A debt-free capital structure materially reduces financial risk and interest obligations, giving management flexibility to allocate scarce capital to R&D or commercialization. Improved equity (~$3.6M TTM) strengthens the balance sheet and extends runway absent near-term large spend shocks.
Negative Factors
Persistent negative cash flow
Despite material improvement, operating and free cash flow remain negative, implying continued funding needs. Persistent cash burn constrains strategic optionality, forces capital-raising or asset sales, and increases execution risk as management must prioritize near-term liquidity over longer-term growth investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free capital structure materially reduces financial risk and interest obligations, giving management flexibility to allocate scarce capital to R&D or commercialization. Improved equity (~$3.6M TTM) strengthens the balance sheet and extends runway absent near-term large spend shocks.
Read all positive factors
Avenue Therapeutics (ATXI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$923.19K
Dividend YieldN/A
Average Volume (3M)2.90K
Price to Earnings (P/E)―
Beta (1Y)0.37
Revenue GrowthN/A
EPS Growth89.68%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,183,426
10 Day Avg. Volume2,401
30 Day Avg. Volume2,901
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.26
Price to Sales (P/S)0.00
P/FCF Ratio-2.87
Enterprise Value/Market Cap-3.02
Enterprise Value/Revenue-1.98
Enterprise Value/Gross Profit-1.98
Enterprise Value/Ebitda0.72
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Avenue Therapeutics Business Overview & Revenue Model
Company Description
Avenue Therapeutics (ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases. The company's core product includes intravenous (IV) tramadol, whi...
How the Company Makes Money
Avenue Therapeutics generates revenue primarily through the development and commercialization of its pharmaceutical products. The company's key revenue stream is expected to come from the sales of its flagship product, IV tramadol, once it gains r...
Avenue Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
55
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -3.85M | -11.70M | 4.05M | -2.44M | 7.00K | -5.15M |
| Net Income | -3.74M | -11.65M | -10.38M | -3.55M | -3.73M | -5.15M |
Balance Sheet | ||||||
| Total Assets | 3.73M | 2.67M | 1.85M | 6.84M | 3.96M | 3.25M |
| Cash, Cash Equivalents and Short-Term Investments | 3.71M | 2.59M | 1.78M | 6.71M | 3.76M | 3.13M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.42M | 816.00K | 1.20M | 3.58M | 509.00K | 886.00K |
| Stockholders Equity | 3.56M | 2.80M | 1.58M | 3.90M | 3.45M | 2.36M |
Cash Flow | ||||||
| Free Cash Flow | -1.74M | -9.03M | -12.45M | -7.60M | -3.75M | -5.61M |
| Operating Cash Flow | -1.74M | -9.03M | -9.45M | -7.60M | -3.75M | -4.61M |
| Investing Cash Flow | 0.00 | 0.00 | -3.00M | 0.00 | 0.00 | -1.00M |
| Financing Cash Flow | 2.85M | 9.84M | 7.53M | 10.54M | 4.38M | 0.00 |
Avenue Therapeutics Technical Analysis
Neutral
0.73
Price Trends
0.28
Positive
0.50
Negative
0.53
Negative
Market Momentum
<0.01
Negative
53.94
Neutral
97.73
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATXI, the sentiment is Neutral. The current price of 0.73 is above the 20-day moving average (MA) of 0.24, above the 50-day MA of 0.28, and above the 200-day MA of 0.53, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.94 is Neutral, neither overbought nor oversold. The STOCH value of 97.73 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ATXI.
Avenue Therapeutics Risk Analysis
Avenue Therapeutics disclosed 57 risk factors in its most recent earnings report. Avenue Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Avenue Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $571.51K | -0.24 | ― | ― | 178.82% | -4121.10% | |
42 Neutral | $923.19K | -0.92 | -121.42% | ― | ― | 89.68% | |
41 Neutral | $428.09K | -0.10 | -63.03% | ― | -100.00% | 86.75% | |
| ― | $2.71M | -0.17 | -168.95% | ― | ― | 90.27% |
* Healthcare Sector Average
ATXI
Avenue Therapeutics
0.29
-0.02
-6.45%
BDRX
Biodexa Pharmaceuticals
0.66
-11.64
-94.63%
QCLS
Q/C Technologies
3.53
-32.47
-90.19%
SCNI
Scinai Immunotherapeutics
0.60
-2.20
-78.54%
OGEN
Oragenics
0.58
-5.90
-91.08%
Avenue Therapeutics Corporate Events
Executive/Board ChangesShareholder Meetings
Avenue Therapeutics shareholders elect directors, ratify KPMG auditor
Positive
Dec 31, 2025
At its 2025 annual meeting of stockholders held virtually on December 30, 2025, Avenue Therapeutics, Inc. shareholders elected six directors — including Jay Kranzler, Faith Charles, Neil Herskowitz, Alexandra MacLean, Curtis Oltmans and Lind...
Shareholder Meetings
Avenue Therapeutics Announces 2025 Annual Meeting Date
Neutral
Nov 18, 2025
Avenue Therapeutics, Inc. has announced December 30, 2025, as the date for its 2025 annual meeting of stockholders. Stockholders must submit proposals for inclusion in the proxy statement by November 28, 2025, to be considered timely, and must com...
M&A Transactions
Avenue Therapeutics Sells Baergic Bio to Axsome
Positive
Nov 12, 2025
On November 5, 2025, Avenue Therapeutics and its subsidiary Baergic Bio entered into an agreement with Axsome Therapeutics for the acquisition of Baergic. Axsome acquired 100% of Baergic’s equity and global rights to BAER-101, now AXS-17, fo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.